The stock of Emergent Biosolutions Inc (NYSE:EBS) is a huge mover today! About 336,390 shares traded hands. Emergent Biosolutions Inc (NYSE:EBS) has declined 33.89% since April 4, 2016 and is downtrending. It has underperformed by 34.98% the S&P500.
The move comes after 9 months positive chart setup for the $979.58M company. It was reported on Nov, 4 by Barchart.com. We have $31.04 PT which if reached, will make NYSE:EBS worth $215.51M more.
Emergent Biosolutions Inc (NYSE:EBS) Ratings Coverage
Out of 3 analysts covering Emergent Biosolutions (NYSE:EBS), 3 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Emergent Biosolutions has been the topic of 5 analyst reports since August 10, 2015 according to StockzIntelligence Inc. As per Monday, August 10, the company rating was upgraded by Zacks. The stock has “Buy” rating given by Chardan Capital Markets on Friday, April 15. The stock has “Buy” rating given by Singular Research on Tuesday, June 28. As per Monday, March 28, the company rating was initiated by Singular Research. The firm earned “Outperform” rating on Friday, February 19 by Wells Fargo.
According to Zacks Investment Research, “EMERGENT BIOSULUTIONS INC. is a leading biopharmaceutical company dedicated to one simple mission – to protect life. EBS develops, manufactures and commercializes vaccines and therapeutics that assist the body’s immune system to prevent or treat disease. Their products target infectious diseases and other medical conditions that have resulted in significant unmet or underserved public health needs. Their marketed product, BioThraxÂ® (Anthrax Vaccine Adsorbed), is the only vaccine approved by the U.S. Food and Drug Administration for the prevention of anthrax infection.”
Insitutional Activity: The institutional sentiment increased to 1.56 in 2016 Q2. Its up 0.33, from 1.23 in 2016Q1. The ratio increased, as 25 funds sold all Emergent Biosolutions Inc shares owned while 55 reduced positions. 35 funds bought stakes while 90 increased positions. They now own 35.17 million shares or 5.50% more from 33.34 million shares in 2016Q1.
Mutual Of America Capital Management Ltd Limited Liability Company accumulated 204,941 shares or 0.12% of the stock. Citadel Advisors Limited Liability Corporation has 0% invested in the company for 14,889 shares. Alliancebernstein Lp last reported 62,812 shares in the company. The Japan-based Blackrock Japan has invested 0% in Emergent Biosolutions Inc (NYSE:EBS). Ahl Llp holds 0.04% or 26,924 shares in its portfolio. Eqis Mngmt reported 60,278 shares or 0.12% of all its holdings. Nordea Ab accumulated 14,773 shares or 0% of the stock. Zurcher Kantonalbank (Zurich Cantonalbank) owns 817 shares or 0% of their US portfolio. Millennium Mgmt Ltd Liability Corporation owns 148,718 shares or 0.01% of their US portfolio. National Bank Of New York Mellon Corporation has 670,318 shares for 0.01% of their US portfolio. Moreover, Mycio Wealth Partners Limited has 0% invested in Emergent Biosolutions Inc (NYSE:EBS) for 500 shares. Royal Comml Bank Of Canada last reported 0% of its portfolio in the stock. Dana Invest Advsrs last reported 44,966 shares in the company. Deere & Co holds 0.02% or 14,526 shares in its portfolio. Lsv Asset Mngmt holds 0.02% of its portfolio in Emergent Biosolutions Inc (NYSE:EBS) for 302,035 shares.
Insider Transactions: Since May 12, 2016, the stock had 0 buys, and 10 sales for $10.67 million net activity. Another trade for 25,000 shares valued at $967,750 was sold by El-Hibri Fuad. $380,494 worth of shares were sold by Abdun-Nabi Daniel on Wednesday, June 1. Shares for $207,364 were sold by JOULWAN GEORGE A. 47,631 Emergent Biosolutions Inc (NYSE:EBS) shares with value of $1.87M were sold by SULLIVAN LOUIS W. The insider Harsanyi Zsolt sold 27,867 shares worth $1.18M. Shares for $180,950 were sold by Hauer Jerome M on Thursday, May 12.
More notable recent Emergent Biosolutions Inc (NYSE:EBS) news were published by: Fool.com which released: “Why Emergent Biosolutions Inc Surged Higher Today” on September 30, 2016, also Fool.com with their article: “Why Emergent BioSolutions Inc. Procured a Lower Price Today” published on June 22, 2016, Forbes.com published: “Emergent BioSolutions Is Oversold” on June 27, 2016. More interesting news about Emergent Biosolutions Inc (NYSE:EBS) were released by: Fool.com and their article: “Emergent BioSolutions Inc. Asks for Patience” published on August 11, 2016 as well as Fool.com‘s news article titled: “Emergent BioSolutions Inc. Expanding Along” with publication date: March 07, 2016.
EBS Company Profile
Emergent BioSolutions Inc., incorporated on December 19, 2003, is a biopharmaceutical firm that offers specialized products to healthcare providers and governments to address medical needs and emerging health threats. The Firm develops, makes and delivers a portfolio of medical countermeasures primarily for government agencies in the areas of biological and chemical threats and emerging infectious diseases (EID). It also develops and commercializes therapeutics, and other specialty products for hospitals and clinics in the areas of hematology/oncology, transplantation, infectious diseases and autoimmune disorders. The Company’s two operating divisions include Biodefense and Biosciences.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.